Testing a new drug to help reduce methamphetamine use
Phase 0/1b Clinical Trial of Novel Therapeutic Agent MT-110 for the Reduction of Methamphetamine Use - Part 2
This study is testing a new treatment called MT-110 to see if it can help people with methamphetamine use disorder stay off the drug by reducing cravings and the urge to use again.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Myosin Therapeutics INC. NIH-funded |
| Lab location | 1 site (Jupiter, United States) |
| Project ID | NIH-11168308 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of a novel therapeutic agent called MT-110 in reducing methamphetamine use among individuals with methamphetamine use disorder (MUD). The study aims to evaluate how this drug can help maintain abstinence by targeting relapse triggers that often lead to a return to drug use. Participants will receive a single intravenous dose of MT-110, and the research will assess its impact on reducing cravings and drug-seeking behavior. The approach is based on preclinical findings that suggest MT-110 can restore brain function affected by methamphetamine use.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are diagnosed with methamphetamine use disorder.
Not a fit: Patients who are not struggling with methamphetamine use disorder or those under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new pharmacotherapy option for individuals struggling with methamphetamine addiction, potentially leading to better long-term recovery outcomes.
How similar studies have performed: Previous research has shown promise in using pharmacological approaches to treat addiction, but this specific drug and its mechanism are novel and have not been widely tested in humans.
Where this research is happening
Jupiter, United States
- Myosin Therapeutics INC. — Jupiter, United States (Active)
Researchers
- Principal investigator: Young, Erica J — Myosin Therapeutics INC.
- Study coordinator: Young, Erica J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.